Article mayhem
   
Nav Menu
select
home
select
Sign up
select
Login
select
Submit Articles
select
Submission Guidelines
select
Top Articles
select
Link Directory
select
About Us
select
Contact Us
select
Privacy Policy
select
RSS Feeds
 
Categories

Accessories
Arts
Business
Cars and Trucks
CGI
Coding Sites
Computers
Cooking
Crafts
Current Affairs
Databases
Entertainment
Film
Finances
Gardening
Healthy Living
Holidays
Home
Internet
Medical
Men Only
Motorcyles
Our Pets
Outdoors
Relationships
Religion
Self Improvement
Sports
Staying Fit
Technology
Travel
Web Design
Weddings
Women Only
Writing
 
Stats
Total Articles: 484031
Total Authors: 137146
Total Downloads: 16169500


Newest Member
Paul Jameson

 


   

Medical Treatments for Erectile Dysfunction


The 1980s saw a raising break away from psychological handling of sexual disorders to an emphasis on surgical and medical solutions for bettering sexual health. At the same time, there was a advanced shift within the medical community and public at large, towards seeing the etiology of sexual disorders as organic, rather than the psychogenic understanding emphasised by sex therapists. Exercise of improved sophisticated diagnostic processes, such as duplex sonography and cavernosograms (although not necessarily bettering treatment) contributed credibility and imprimatur to the importance of organic pathogenesis. This was particularly true in the area of erectile dysfunction, where urologists evidenced control, with the prosperous marketing and practice of different intracavernosal and intraurethral systems. Although highly bragged by urologists, the treatment efficacy of these products was offset by their intrusiveness into the patients bodies and reduction in spontaneity, their models of use essential.

Initially, there were few oral treatments for erectile dysfunction, being utilized by urologists, such as yohimbine based products, trazodone, and bupropion. They had only modest proerectile capability. Pharmaceutical companies were inspired to follow up on oral treatments with the promise of less intrusiveness and even larger benefits. The first visible evidence of accomplishing that predict was the sildenafil launch. Accompanying to Pfizers success, multiple companies simultaneously pursued clinical tests of easy-to-use handling for male sexual disorders. Among others, these included additional PDE-5 type compounds and other oral treatments, such as ixense, and topically implemented compounds. Additionally, PT-141 (Palatin Technology, Cranbury, NJ, USA) is a nasally administered peptide that is under development, which is assumed to work through a central nervous system mechanism.

Currently, there are three highly effective PDE-5, FDA-approved treatments for erectile dysfunction: sildenafil, vardenafil, and tadalafil. Reviews of long-term extension analyses and released accounts of usage in clinical practice show that sildenafil's strength was maintained with long-term treatment. Importantly Combination Therapy for Sexual Dysfunction better erectile function was proved for sildenafil compared with placebo for all efficacy parameters studied, regardless of patient age, race, body mass index, erectile dysfunction etiology, erectile dysfunction severity, erectile dysfunction duration, or the presence of various co morbidities. Long-term effectivity was assessed in three open-label reference studies. Vardenafil (launched in 2003) is a potent, selective PDE-5 inhibitor, which improved erectile function in a broad population of men with erectile dysfunction and in characteristically challenging-to-treat groups such as diabetic and post prostatectomy patients. Tadalafil also launched in 2003, when taken, as needed before sexual activity and without restrictions on food or alcohol intake, significantly better erectile function. It permitted a essential proportion of patients to reach a normal IIEF erectile function domain score, exposed a broad window of therapeutic responsiveness and was well permitted in a representative population of patients with broadspectrum erectile dysfunction.



Author Resource:- David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

[Valid RSS feed]  Category Rss Feed - http://www.articlemayhem.com/rss.php?rss=88
By : David Jamesonsess    29 or more times read
Submitted 2010-05-20 22:20:45
Article From Article Mayhem

ezine ready view Ezine ready view

Related Articles

 
 


[Valid RSS feed]